University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 0C-18-16


A Phase 1/2 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects With Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Cristina De Leon, Coordinator, Deborah Fridman, Coordinator, Lorraine Martinez, Coordinator, Maria Sharma, Coordinator, Leila Andres, Coordinator, Nicole Jensen, Coordinator, Rishi Bhavsar, Coordinator, Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Taison Tran, Coordinator, Arthur Alvarez, D.M., Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Atessa Kiani, Coordinator, Alda Inveiss, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.